Genus PLC
07 November 2007

For Immediate Release 7 November 2007

Genus plc
('Genus' or 'the Company')

Publication of Prospectus
Move to the Official List

Genus plc (AIM: GNS), a world leading animal genetics company, is pleased to announce that it has published its prospectus in connection with the proposed listing of its entire issued ordinary share capital on the Official List of the UK Listing Authority and admission to trading on the London Stock Exchange's market for listed securities ('Admission').

It is expected that Admission will become effective and that dealings on the London Stock Exchange's main market will commence at 8.00 am on Monday 12 November 2007. Trading in the Company's ordinary shares on AIM will be cancelled simultaneously.

The Company's stock code will continue to be LSE: GNS (GNS.L for Reuters and GNS LN for Bloomberg) and there will be 59,204,190 ordinary shares in issue on Admission.

Copies of the prospectus are available from the 'Investors' section of the Company's website at www.genusplc.com. The prospectus has also been submitted to the UKLA's Document Viewing Facility situated at: Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

For further information, please contact:

Genus plc Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director

Landsbanki Securities (UK) Limited Tel: 020 7426 9000
Nominated Adviser & Joint Broker
Shaun Dobson

Buchanan Communications Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks

About Genus

Genus creates and sells added value products for livestock farming and food producers by creating advances to animal breeding through biotechnology. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals

with superior genetics to those animals currently in production. Customers produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain.

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries on five continents, with research laboratories located in Madison, USA.

This information is provided by RNS
The company news service from the London Stock Exchange